These updates showcase
Astellas Pharma Inc. in a mixed light, covering dividend announcements, gene therapy agreements, drug approvals, financial results, and employee reductions.
Initiatives in Tanzania were noted, meanwhile short interest in Astellas dropped by 58.7% in December. A dividend of ¥37.00 was announced. Astellas and
AviadoBio unveiled an exclusive option and a license agreement for AVB-101, targeting dementia. Despite a team member being indicted by China's prosecutors, Astellas continues to ink business agreements, recently with Axcelead DDP for targeted protein degraders. A highlight was the unveiling of a new Life Sciences Center in Cambridge, to expedite breakthrough therapy discovery. Astellas pursued partnerships for advanced cancer treatment and gene therapy. However, Astellas also announced closures for its Biomanufacturing Facility impacting about 100 employees. A persistent focus was put on treatments like VEOZA™ and VYLOY™, which gained regulatory approvals in several regions. Moreover, an AI-Powered Heart Failure Management System was launched, and Astellas' new facility broke ground in Ireland, indicating continued growth.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Fri, 17 Jan 2025 23:23:16 GMT -
Rating 4
- Innovation 8
- Information 7
- Rumor 2
